Boosting with poxviruses enhances Mycobacterium bovis BCG efficacy against tuberculosis in guinea pigs.
Tuberculosis is rising in the developing world due to poor health care, human immunodeficiency virus type 1 infection, and the low protective efficacy of the Mycobacterium bovis BCG vaccine. A new vaccination strategy that could protect adults in the developing world from tuberculosis could have a huge impact on public health. We show that BCG boosted by poxviruses expressing antigen 85A induced unprecedented 100% protection of guinea pigs from high-dose aerosol challenge with Mycobacterium tuberculosis, suggesting a strategy for enhancing and prolonging the efficacy of BCG.
Williams
A
A
Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford OX3 7BN, United Kingdom.
Goonetilleke
N P
NP
McShane
H
H
Clark
Simon O
SO
Hatch
Graham
G
Gilbert
S C
SC
Hill
A V S
AV
D000818:Animals; D000942:Antigens, Bacterial / Q000235:genetics* / Q000276:immunology; D001500:BCG Vaccine / Q000276:immunology*; D006168:Guinea Pigs; D011212:Poxviridae / Q000235:genetics*; D014376:Tuberculosis / Q000517:prevention & control*; D014614:Vaccines, Synthetic / Q000276:immunology*
D000942:Antigens, Bacterial; D001500:BCG Vaccine; D014614:Vaccines, Synthetic; C065036:antigen 85, Mycobacterium bovis